Taiwan 'breakthrough therapy' drugs to enter clinical trials

Two new drugs, developed by a Taiwanese company for the treatment of schizophrenia and designated by the U.S. Food and Drug Administration (FDA) as breakthrough therapy, will undergo late stage trials this year, according to the company's founder and CEO.

(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)